EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir

Michael D Waters iD, Stafford Warren, Claude Hughes, Philip Lewis, Fengyu Zhang

Environmental and Molecular Mutagenesis · 2022-01 · 63 (1) · 37-63

DOI: 10.1002/em.22471 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Environmental and Molecular Mutagenesis, online erschienen am 28.01.2022. Verfasst von Michael D Waters und 4 weiteren Autor:innen. Beteiligte Einrichtung: Michael Waters Consulting USA, Hillsborough, North Carolina, USA. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 185 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review considers antiviral nucleoside analog (NA) drugs, including ribavirin, favipiravir, and molnupiravir, which induce genome error catastrophe in SARS‐CoV or SARS‐CoV‐2 via lethal mutagenesis as a mode of action. In vitro data indicate that molnupiravir may be 100 times more potent as an antiviral agent than ribavirin or favipiravir. Molnupiravir has recently demonstrated efficacy in a phase 3 clinical trial. Because of its anticipated global use, its relative potency, and the reported in vitro “host” cell mutagenicity of its active principle, β‐d‐N4‐hydroxycytidine, we have reviewed the development of molnupiravir and its genotoxicity safety evaluation, as well as the genotoxicity profiles of three congeners, that is, ribavirin, favipiravir, and 5‐(2‐chloroethyl)‐2′‐deoxyuridine. We consider the potential genetic risks of molnupiravir on the basis of all available information and focus on the need for additional human genotoxicity data and follow‐up in patients treated with molnupiravir and similar drugs. Such human data are especially relevant for antiviral NAs that have the potential of permanently modifying the genomes of treated patients and/or causing human teratogenicity or embryotoxicity. We conclude that the results of preclinical genotoxicity studies and phase 1 human clinical safety, tolerability, and pharmacokinetics are critical components of drug safety assessments and sentinels of unanticipated adverse health effects. We provide our rationale for performing more thorough genotoxicity testing prior to and within phase 1 clinical trials, including human PIG‐A and error corrected next generation sequencing (duplex sequencing) studies in DNA and mitochondrial DNA of patients treated with antiviral NAs that induce genome error catastrophe via lethal mutagenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentAmidesAntiviral AgentsCytidineDNA DamageDeoxyuridineGenome, HumanHumansHydroxylaminesMutagenesisNucleosidesPyrazinesRibavirinSARS-CoV-2

Stichwörter der Autor:innen

5-(2-chloroethyl)-2′-deoxyuridineCOVID-19 pandemicfavipiravirmolnupiravirribavirinβ-d-N4-hydroxycytidine

Substanzen

AmidesAntiviral AgentsHydroxylaminesNucleosidesPyrazinesRibavirinCytidine5-(2-chloroethyl)-2'-deoxyuridineN(4)-hydroxycytidinefavipiravir

Autor:innen und Institutionen

  • Michael Waters Consulting USA, Hillsborough, North Carolina, USA.
  • Anne Arundel Medical Center, Annapolis, Maryland, USA.
  • Duke University Medical Center, Durham, North Carolina, USA.
  • Cornell University, Ithaca, New York, USA.
  • Global Clinical and Translational Research Institute, Bethesda, Maryland, USA.

ORCID-Profile: Michael D Waters

Zitieren

APA

Waters, M. D., Warren, S., Hughes, C., Lewis, P., & Zhang, F. (2022). Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. Environmental and Molecular Mutagenesis, 63(1), 37-63. https://doi.org/10.1002/em.22471

Vancouver

Waters MD, Warren S, Hughes C, Lewis P, Zhang F. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. Environmental and Molecular Mutagenesis. 2022;63(1):37-63. doi:10.1002/em.22471

BibTeX
@article{Waters2022,
  author = {Waters, Michael D and Warren, Stafford and Hughes, Claude and Lewis, Philip and Zhang, Fengyu},
  title = {Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir},
  journal = {Environmental and Molecular Mutagenesis},
  year = {2022},
  volume = {63},
  number = {1},
  pages = {37--63},
  doi = {10.1002/em.22471}
}
Kostenlos starten →